An ongoing dialogue on HIV/AIDS, infectious diseases,
June 2nd, 2019
A Highly Subjective Guide to Clinically Important Infections That Have Changed Names
Why do many clinically important microorganisms change names?
They haven’t married and taken their spouse’s name or gone to Hollywood and adopted a stage name.
Instead, through the tireless work of microbiologists, taxonomists, and geneticists, they have undergone sufficient reclassification so that their old name just doesn’t make sense anymore.
Or more graphically:
Why do clinical microbiologists love taxonomy? https://t.co/BdgGEUOFlh @ASMicrobiology #ASMClinMicro pic.twitter.com/fL3qgemYea
— JClinMicro EIC (@JClinMicro) May 17, 2019
What we gain in accuracy, alas, is accompanied by an increase in confusion, and a heavy taxation on our memory reserves. Even we ID types can barely keep the names straight; imagine how non-ID clinicians feel?
Our colleagues in clinical microbiology recognize this problem — really they do. But spend a little time reading Name Changes for Fungi of Medical Importance, and pretty soon you get deep into the weeds with no available machete to hack your way out. How’s this for an example?
The Ajellomycetaceae contains the teleomorph species Ajellomyces dermatitidis, Ajellomyces capsulatus, and Ajellomyces duboisii, the anamorphs of which are the genera Blastomyces and Histoplasma. The Ajellomycetaceae also contains some genera that have no known teleomorphs, including Paracoccidioides and the newly described genus Emergomyces.
Well, I’m sure glad we cleared that up!
So if you’re looking for an in-depth, detailed review of some recent name changes, take a look at the references section in this editorial, kindly sent to me by ID doctor and medical microbiologist Kim Henson. Warning — they are not for the faint of heart!
But here is a more subjective list of name changes that I’ve weathered over the years, along with a few miscellaneous comments:
Clostridium difficile became Clostridioides difficile. This recent change will take a while to get used to, as it’s such a common infection that Clostridium is pretty hardwired in our neural circuits. Also, the ubiquitous abbreviation “C. diff” still works fine, so there’s not much motivation to learn how to write, or to say, Clostridioides — in fact, I just had to teach my spell checker not to flag it.
Pneumocystis carinii became Pneumocystis jirovecii. It’s now quite clear that pneumocystis is a fungus (and not a protozoan, as originally thought). It’s also widely accepted (finally) that the species encountered in corticosteroid-treated rats is different from the one infecting humans — the rat gets Pneumocystis carinii, and humans Pneumocystis jirovecii. What’s still a matter of substantial debate is how to abbreviate the pneumonia caused by Pneumocystis jirovecii, as demonstrated by this hotly-contested poll:
What's the current preferred abbreviation for Pneumocystis jirovecii pneumonia? cc @UpToDate #IDtwitter https://t.co/uIq2dJEb1S
— Paul Sax (@PaulSaxMD) May 11, 2019
Haemophilus aphrophilus became Aggregatibacter aphrophilus. I attended a meeting a few years back which included several other ID geeks like myself, and we were discussing various aspects of our work. One mentioned she had just seen a case of endocarditis due to the wonderfully named Cardiobacterium hominis, which is of course the “C” in the HACEK group of organisms. I then mentioned that Haemophilus aphrophilus had been renamed Aggregatibacter aphrophilus — and suddenly there was a palpable sadness in the room. How could anyone be so heartless as to change the name of this whimsical and mellifluous-sounding microbe? Such a deep injustice, we’re still in mourning.
Streptococcus milleri became Streptococcus anginosus, intermedius, and constellatus. The name change to these abscess-forming streptococcal infections happened so long ago that many youngsters out there might not have even heard of Strep milleri. But trust me, it was tricky enough that for a while these three species were called “Strep milleri group” to help bridge the pain; now they’re called “Streptococcus anginosus group,” and milleri is no more. For the record, streptococcal taxonomy is mega-complicated and confusing — but if you think that is bad, wait until you start getting into the fungi!
Pseudallescheria boydii became Scedosporium boydii. Big improvement — Scedosporium is a wonderful word, replacing the strange and unspellable Pseudallescheria. I remember attending an ID conference during medical school that had two cases, both of which included details that caused me great confusion. The first was a streptococcal endocarditis case complicated by a “mycotic aneurysm.” Aren’t fungal infections called “mycoses”? So how did the strep cause a fungal complication — isn’t it a bacterial infection? (Turns out any infectious aneurysm is called “mycotic” — who knew?) The second was a post-traumatic fungal infection due to Pseudallescheria boydii, which I heard as “Pseudo …” which of course means “not genuine” or “sham” — you know, like “pseudo-intellectual.” So, if Pseudallescheria is the fake one, what’s the real one? I guess the real one is Scedosporium. Or not — fungal taxonomy is a total mess, right Andrej?
Just when you thought you understood Scetosporium. It gets more complicated, more difficult to treat, and like all of fungus, a taxonomic mess. #MSGERC2018 #MedEd pic.twitter.com/xZ7J0XABlv
— Andrej Spec, MD, MSCI (@FungalDoc) September 27, 2018
Propionibacterium acnes became Cutibacterium acnes. Of all the recent name changes, this is easily my favorite! I have already thoroughly embraced this new name, and even pedantically correct people stuck on the old one — making me excellent company on rounds. Maybe Cutibacterium will give greater attention to this under-appreciated pathogen, infamous for causing prosthetic joint (especially shoulder) and neurosurgical infections. And why do I like it? First, Propionibacterium is a devil to say, good riddance. Second, Cutibacterium is adorable, especially if you pronounce it “Cutie-bacterium.”
Xanthomonas maltophilia became Stenotrophomonas maltophilia. This problematic, highly antibiotic-resistant gram-negative rod changed names long ago — so as with Streptococcus milleri, many might not even have heard of Xanthomonas. I first learned about this bug when imipenem had just been FDA-approved (yes, I’m that old), as it is one of the rare gram negatives intrinsically resistant to carbapenems. Two other points worth emphasizing: 1) Xanthomonas sounds very cool, could almost be the name of a science fiction series, “The Galactic Empires of Xanthomonas”; 2) Stenotrophomonas is real mouthful. Takes a while to learn how to say that comfortably — which is why, to many cystic fibrosis clinicians and patients, it’s just known as “steno.”
Enterobacter aerogenes became Klebsiella aerogenes. C’mon, that’s just mean, flipping one enteric gram-negative rod name to another. I suppose we’ll get used to it eventually, grumble grumble.
Rochalimaea henselae became Bartonella henselae. These agents of cat scratch disease, endocarditis, bacillary angiomatosis, and peliosis hepatis haven’t been Rochalimaea for many years. But my friend Joel Gallant used to call my other friend Rochelle Walensky “Rochalimaea” long ago when they were at Johns Hopkins together — which just goes to show that we ID doctors have a very strange sense of humor, one that may be difficult to explain to others.
Diphyllobothrium latum became Dibothriocephalus latus. This fish tapeworm of gefilte fish fame wasn’t easy to learn in medical school, so I’m going to resist this change for as long as possible. Note that even CDC hasn’t updated their page, taxonomy notwithstanding, so I appear to be on safe ground holding out at least for now. Dibothriocephalus indeed, hmmph. Try saying that three times fast.
Penicillium marneffei became Talaromyces marneffei. This dimorphic fungus, endemic to Southeast Asia, causes disseminated disease in severely immunocompromised hosts. I always liked that we had a clinically important fungus that included the name Penicillium, reminding us of the source of our first beta lactam antibiotic. Oh well. This Talaromyces name is taking a while to get used to, probably because it’s not a common infection here.
Pseudomonas cepacia became Burkholderia cepacia. It hasn’t been Pseudomonas cepacia for ages. But did you know that Burkholderia cepacia is really at least two different species, Burkholderia multivorans and Burkholderia cenocepacia? Isn’t microbiology fun?
Streptococcus bovis became Streptococcus gallolyticus — and a whole host of other things. Medical school curricula indelibly impart certain ID facts to every student — three of them are 1) daptomycin is inactivated by lung surfactant; 2) listeria and its various dietary associations; and 3) endocarditis due to Streptococcus bovis should prompt a look for colon cancer. However, they haven’t yet gotten around to updating the species name, perhaps because hardly anyone remembers it. And did I mention that streptococcal taxonomy is confusing, irrational, and complicated? Sure I did, many times — and further reviewed the whole clinical world of clinical streptococcal infections here.
And last, but not least …
Ixodes dammini became Ixodes scapularis. Hey, no fair — I have enough trouble with microorganism taxonomy, do I have to start keeping track of insects arthropods too? All I know is that Gustave Dammin was an esteemed pathologist here at the Brigham for many years, and studied both Lyme Disease and babesiosis. Which begs the question — is it an honor, or a curse, to have such a nasty little critter named after you? Let the debate begin.
Any other name changes that deserve highlighting?
May 27th, 2019
A Day in the Life of a Malaria Diagnosis “Lab” — with Apologies to Twitter’s “Thoughts of Dog”
Scene: A quiet morning, somewhere in sub-Saharan Africa. A few roosters crow in the distance. A black Labrador Retriever slowly rouses herself from sleep.
ah. nice long nighttime snoozle. my favorite thing. ending soon.
but many favorite things. partial list. i’m good with lists.
1. belly rub.
c. peanut butter.
4: stuffed toy lamb, with squeak. though missing ear now. because we played too much.
7. tennis ball left out in park. for weeks. better after warm rain. and other doggos chew.
g. last but should be first. you.
list could be longer. but hear sound of human. half open eyes. no one here yet.
back to snoozetown? not quite.
hear human sound again, coming down steps. now he’s on ground. with me. eye to eye.
nice pet behind ears. hmmm. but one ear left inside out. that’s ok. i forgive easy.
Who’s a good girl?
silly question. of course. i am. but he asks this a lot. so i tell him. i’m awesome.
stretch legs. long yawn.
Time for work! Are you ready?
not work to me. my new favorite game. there are treats. simple rules. another list.
1. take socks from small humans.
(they smell delicious. especially socks of teenage boy humans. after playing football in African heat. yum.)
d. sniff socks of small humans.
7. some smell different. sad.
Work has shown that people infected with malaria parasites produce a body odour that is detected by mosquitoes, which results in malaria mosquitoes preferentially feeding on asymptomatic, malaria-infected individuals.
g. tell human which sock is sad. sometimes i just stay. sometimes bork.
5. best part. crunchy treat.
i could do this all day. especially if it helps small human. and if there are treats.
watch.
(Inspired by a recently published paper, a brilliant Twitter feed (“only” 2.6 million followers), and h/t Rich Davis for the clever pun in the title.)
May 19th, 2019
CDC Does Us a Huge Favor by Advising Against Annual Screening of Healthcare Workers for Latent TB
There are definitely things we do in medicine just because that’s how we’ve always done them.
Among these evidence-free actions, we can include yearly screening for latent TB infection (LTBI) in all healthcare workers
If we carefully examine the rationale behind this practice — as this thorough review nicely does — one would be hard-pressed to find any other reason for this time- and labor-intensive annual flog.
Why does annual LTBI screening make no sense?
- Evidence from clinical studies that this strategy reduces TB incidence in US healthcare workers? Zero.
- Incidence of TB in the US over the past several decades? Steadily down, now at historic lows.
- Conversion of tuberculin skin tests (TSTs) or interferon gamma release assays (IGRAs) among healthcare workers without an obvious TB exposure? Vanishingly rare.
- The testing is easy-to-do, highly accurate, and inexpensive? No to all.
Indeed, that’s why the new recommendation, from a joint effort by the National Tuberculosis Controllers Association and CDC, is so welcome:
In the absence of known exposure or evidence of ongoing TB transmission, U.S. health care personnel … without LTBI should not undergo routine serial TB screening or testing at any interval after baseline (e.g., annually).
Extra points for clarity!
Encouragingly, all the ID and TB specialists I’ve queried lend their enthusiastic support to this change in policy. And this includes that extremely careful bunch who specialize in infection control.
Now we just need to turn this policy into action — which can start by dismantling serial testing requirements in hospitals and other healthcare facilities nationally.
Think what we can do with all that freed-up time!
Maybe even correct spelling errors on fax cover sheets.
"My name is Sax — that's spelled S-A-X, like the musical instrument."
Have been saying that for decades, so guess something like this fax cover sheet was bound to happen eventually. (With apologies to spell-checkers everywhere.) pic.twitter.com/3KMsJt7kO8— Paul Sax (@PaulSaxMD) May 16, 2019
May 12th, 2019
On Mother’s Day, a Tribute to a Mother Who Doesn’t Celebrate Mother’s Day
My siblings and I are pretty lucky, because our mother may be the smartest person in the world.
Let me reassure you that this is not just our biased opinion. Everyone who knows her well thinks the same thing — including my wife, who told me today, on Mother’s Day, that my Mom’s remarkable brainpower should be the focus of this profile.
(Not that my mother has any time for Mother’s Day. Unsentimental in the extreme, she disparages such holidays as manipulative.)
I first had an inkling of her intellectual superpower when, after underperforming on an important test in middle school due to numerous trivial distractions (baseball, model rockets, general silliness), I received some stern comments of disapproval from my father.
When my mother rushed to my defense, he countered as follows:
Look, no one is as smart as your mother. Most people have to study to do well in school.
I assure you this was said without the slightest exaggeration.
The first person in her family to attend college, she graduated early then followed the path of many women of her generation — married at 21, done having three children by 26 (!), she could have continued down this path of domesticity without anyone even noticing.
That’s what most women did.
But she went back to get a graduate degree (abandoning little me at home, sob), then started a successful career as a food writer, continuing to work as a journalist (Newsday, New York Daily News, Bon Appetit) for many years. In 2000, as the internet took off, she won a James Beard award for Best Internet Writing.
As this point, I know what you’re thinking — how could a food writer be the smartest person in the world? Surely that honor must go to a neuroscientist, a mathematician, a scholar of ancient histories, some super-linguist who speaks 20 languages.
Well, here are a few examples:
- Technology. Most people my mother’s age really don’t do well with new technology — remember the flashing clock on the VCR? But my mother was an early adopter of computers, owner of one of the first word processors — does this Wang 2200 look familiar to anyone? Although she’s not writing code or macros, she effortlessly uses computers and cell phones as tools to get things done — which is probably what most of us should do rather than obsess over the latest gadget.
- Breadth. My mother’s expertise extends way beyond food — literature, art, music, movies, theater, current events, all seem to be in her domain. My daughter is constantly amazed at how her grandmother — my mother — gets most pop culture references. During a video interview I did with many family members at the turn of the century, I asked her what she believed to be the greatest unheralded work of art. She paused briefly and said: “Eugene Onegin — and that’s because I just read the novel, saw the opera, and rented the movie.”
- Math and science. Though she has degrees in art history and English literature, I can talk to her about advances in medicine and science without the slightest need to bring down the level. It’s particularly remarkable how quickly she grasps key principles of clinical research and epidemiology, concepts that many of us spend years mastering — examples include confounding, sensitivity and specificity, lead-time bias, the potential harms of excessive screening. Explain these principles once, she gets them forever.
Not included in the above Mother’s Day (sorry Mom!) tribute is that she’s been consistently supportive of my brother, sister, and me in all our life and career decisions. When I ditched a cardiology fellowship for the much less remunerative — and even stigmatized — specialty of infectious diseases, she never once even hinted at displeasure.
So thank you, Dad, for choosing this very smart and wonderful person to be our mother.
She’s so special that I can even forgive her these two transgressions, both of which stem from this aforementioned lack of sentimentality:
- She threw away my baseball cards when I went to college. Why should anyone save these boring pieces of cardboard?
- She doesn’t get this whole dog thing. After all, they’re just animals.
Hey Mom, Louie forgives you, too.
May 5th, 2019
Latest Published Study on HIV Treatment as Prevention Is Déjà Vu All Over Again, But Some News Is So Good It Never Gets Old
Even if you’re not an ID or HIV specialist, there’s an excellent chance you’ve heard of the PARTNER2 study, just published in The Lancet.
If not, the title could not be more descriptive:
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy
And, in case you’ve just awoken from a Rumpelstiltskin Rip Van Winkle-length sleep, here are the results:
The risk is essentially zero.
This is far from the first time we’ve heard this information, either from this or other (HPTN 052, Opposites Attract) studies.
The formal publication of PARTNER2 therefore has a déjà vu quality to it, one which prompted Myles Helfand, the indefatigable and entertaining Executive Editor of the terrific HIV resource TheBody, to post the following:
Breaking: A fact we've already known conclusively for about three years https://t.co/YYML1z8igh
— Myles Helfand (@MylesatTheBody) May 3, 2019
“Breaking” indeed. Ha. To Myles, and to many of us, this is old news. The publication of the paper after years of comparable findings from this and other studies may seem anticlimactic, no big deal.
He’d no doubt cite that even this particular study was presented first at the AIDS 2018 conference last summer in Amsterdam. That’s over 8 months ago! Ancient history!
But here’s another take from Claire Farel, an ID doctor from the University of North Carolina (and, full disclosure, a wonderful graduate of our ID fellowship program):
Another boost to our conviction that #UequalsU and hopefully to the fight against #HIV stigma. Discussing U=U with patients has been a gift, leading to some of the most profound conversations I’ve had in medicine. Also, there’s never enough Kleenex. https://t.co/jC7iMhSQZ8
— Claire Farel (@claire_farel) May 3, 2019
(For those not in our field, that “U=U” stands for “Undetectable = untransmittable.”)
First, I am in complete agreement that telling people with HIV that their treatment prevents viral transmission is a “gift,” leading to profound and anxiety-relieving responses. It’s just as good as informing patients that if they take their HIV meds, they will not die of AIDS — and both pieces of information are equally true.
Conveying this information elicits such relief that yes, tears of happiness are often part of the mix, if you’re wondering about that Kleenex reference.
Second, the publication of a study in a peer-reviewed journal still lends far greater authenticity to scientific data than conference presentations or abstracts. This is particularly true when the journal publishing the paper is a prestigious one, such as The Lancet.
(I have cleared it with the Editorial Office that we’re allowed here at NEJM Journal Watch to write that The Lancet is prestigious. Note I didn’t say MOST prestigious.)
Don’t get me wrong — I agree that conference presentations play a critical role in rapidly getting important new data into the public domain. But there’s still room for distribution the old-fashioned way, in a journal, which is why I posted both Myles’s and Claire’s responses to this publication.
Before we leave this study, we must linger for a moment on the most unintentionally amusing sentence from PARTNER2.
It’s this:
In total, couples reported having condomless anal sex approximately 76,088 times during eligible couple-years of follow-up.
Something about the precision of that estimate — are they sure it wasn’t 76,089? — makes me smile every time.
April 28th, 2019
Even More Fun with Old Medical Images
Loyal readers of this site might note that we periodically stray from incisive, topical coverage of our exciting field of Infectious Diseases, and venture off into subjects that may or may not be ID-related.
And good news for fans of this approach, because today it’s time to release our third episode of Fun with Old Medical Images.
Why today? The simple answer is that this feature appears on this site during certain holidays on the pre-Columbian Mesoamerica calendar, a calendar widely used by the Maya for centuries. I find it an excellent resource when trying to solve difficult scheduling problems.
As a reminder, here’s how Fun with Old Medical Images works: I choose an old image from the vast National Library of Medicine collection. Then, I make up a caption and provide a brief commentary.
All this is done for you free of charge — guaranteed without hidden registration or subscription fees.
Off we go, #1:
What a generous group! And you go, Bailey — such a good boy, sitting so still. And those pointy, asymmetric ears are adorable.
Let’s move right on to #2, into the OR:
Not surprisingly! And I’m growing more dubious about Dr. Griswold’s Viennese studies every day.
#3 finds us in a recreational pool for frogs:
Say one thing for Freddy — he sure is fit! But doesn’t he know it’s time for dinner?
And in case you’re wondering, these two images are an old test for strabismus. Somehow.
Speaking of pairs, I bring you two trendy guys for #4:
I hear everyone’s been doing it — The Naked Bald No-Neck Strut. Kids today and their crazy dances!
Heading to #5, with a big challenge in our appearance-obsessed, digital era:
Alas, Connor — dates will have to learn not to judge a book by its cover, your skilled Photoshop efforts notwithstanding.
Finishing with an even half-dozen, here’s #6, which brings us back to familiar ID territory:
Oh, you silly tuberculosis bacillus — we know how to find you!
So that wraps up today’s tour of Even More Old Medical Images. Please join us next time when we’ll be back with our usual erudite content.
But until then, enjoy this:
April 22nd, 2019
Two New Trials of Combination Therapy for MRSA Bacteremia Answer Some Questions — and Raise Several New Ones
Every clinically active ID specialist, hospitalist, and cardiologist realizes that treatment of bacteremia due to methicillin-resistant Staph aureus (MRSA) is no easy task.
In fact, it’s a problem so difficult that persistent bacteremia due to MRSA deserved highlighting here as an “Unanswerable Problem in Infectious Diseases”.
I wrote that over 5 years ago, and you know what? It’s still unanswerable!
One likely reason for the difficulty is that vancomycin kind of stinks as an antibiotic — there are molecular, pharmacologic, and potentially even immunologic reasons why it underperforms compared to beta-lactams.
Now, we have two new clinical trials to help move the field forward.
The first is the CAMERA2 study, just presented by Steven Tong at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), with summary below thanks to Erin McCreary:
.@syctong presents 📸 2️⃣ data at #ECCMID2019. Three-year trials conducted at 27 sites with 356 patients randomized. pic.twitter.com/kwb7UaulJW
— Erin McCreary (@ErinMcCreary) April 16, 2019
The study asked the question of whether adding a beta-lactam to standard of care therapy (vancomycin or daptomycin) would improve outcomes for adults with MRSA bacteremia. Some 356 adults were randomized to receive either monotherapy (vancomycin mostly, with some daptomycin) or combination therapy of vancomycin or daptomycin plus 7 days of an anti-staphylococcal beta-lactam (flucloxacillin, cloxacillin, or cefazolin).
The primary outcome was a composite one of several endpoints, looking at:
- 90-day mortality
- Persistent bacteremia at day 5 or beyond
- Microbiological relapse
- Microbiological treatment failure (positive sterile site culture for MRSA at least 14 days after randomization)
As pictured here, there was no significant benefit of combination therapy over standard of care — even though clearance of bacteremia was faster in the combination arm. The limitations of time to blood culture clearance as a surrogate endpoint echo what we learned previously when evaluating adding aminoglycosides to beta-lactams for treatment of MSSA — faster clearance of blood cultures, but no clinical benefit.
Importantly, participants who received combination therapy had significantly more acute kidney injury, and numerically higher mortality, leading to early termination of the trial. The post-hoc analysis showed that this renal toxicity was far greater with flucloxacillin/vancomycin than cefazolin/vancomycin, and hence the former cannot be recommended.
So, is that the end of combination therapy of vancomycin plus a beta-lactam for MRSA? Certainly not — as noted above, vancomycin treatment strikes most of us as suboptimal, and daptomycin is no better. In addition, the vancomycin/cefazolin strategy in CAMERA2 appears to be safe and may provide greater antimicrobial activity without increasing toxicity. The lead author suggested that this combination may be the next one tested by this group.
The second clinical study in MRSA bacteremia is a recently published pilot trial that randomized 40 patients with MRSA bacteremia to receive either vancomycin or the combination of daptomycin plus ceftaroline — italicized since it is the only FDA-approved beta-lactam with activity against MRSA, and hence fundamentally different from the combination strategy tested in CAMERA2.
Here are the surprising results:
Although the study was initially designed to examine bacteremia duration, we observed an unanticipated in-hospital mortality difference of 0% (0/17) for combination and 26% (6/23) for monotherapy (P=0.029), causing us to halt the study.
Wow.
But before we get too excited, here’s a critically important caveat — with such small numbers, these results could have occurred by chance, especially due to an imbalance of randomization (there were more patients with advanced lung cancer in the monotherapy arm). The authors acknowledge that the results must be considered preliminary due to the small sample size, and strongly encourage a fully powered study of this approach. Agree!
But what about ceftaroline alone? The drug is only FDA-approved for skin/soft-tissue infections and pneumonia; the lack of controlled data on ceftaroline therapy for bacteremia is an unfortunate data gap.
So, here’s a proposed study for MRSA bacteremia — a three-arm, randomized trial comparing:
- Standard-of-care (vancomycin or daptomycin, investigator’s choice)
- Ceftaroline alone
- Daptomycin/ceftaroline
Hey, we ID doctors can dream, can’t we?
April 14th, 2019
Here’s One “Rule” of Medical Education That Needs Fixing — Or at Least a Little Context
Like any card-carrying ID doctor, I enjoy teaching about antibiotics. Give me a whiteboard (small group), or a PowerPoint set-up (lecture hall), and I’m off and running.
Not surprisingly, an important theme of these talks revolves around avoiding antibiotic overuse. Over the years, I’ve collected a few egregious examples of how marketing distorts public perception of antibiotics — and, in particular, their indications.
These images are fun to show in my talks — and, quite explicitly, to mock.
Here’s one:
Free Antibiotics! Just in time for “Cold and Flu Season!” How generous!
And here’s another, an ad I spotted on the NYC subway a couple of years ago:
“Very, very strong antibiotics” for someone who “sneezed.” Brilliant. Those strong antibiotics will be just the thing.
Let me state the obvious — these ads reinforce the very wrong belief that people with viral respiratory tract infections benefit from antibiotics. This misconception drives much of the inappropriate antibiotic prescribing in outpatient care and emergency rooms.
By showing the images, I’m hoping to demonstrate just how pervasive these incorrect views are. It’s a brief and entertaining (I hope) diversion from the more didactic parts of the talk.
But not so fast — the last two times I submitted slides for post-graduate courses, I received notice that these images were in violation of Accreditation Council for Continuing Medical Education (ACCME) standards, specifically:
STANDARD 4.3Educational materials that are part of a CME activity, such as slides, abstracts and handouts, cannot contain any advertising, corporate logo, trade name or a product-group message of an ACCME-defined commercial interest.
But here’s a question for the ACCME folks — doesn’t the context of these images matter? This usage is hardly promotional. It’s just the opposite, I’m making fun of these ads.
And here’s a second question — do you think we live in an advertising-free world? Wouldn’t the learners’ education be furthered by seeing examples of how misleading commercial claims can be?
One of the two courses relented when I made my point — slides stayed in. The other one, no such luck. I’m taking my revenge out on this inexplicable ruling by posting the images here.
But all this back and forth reminded me of this quite brave (and brilliant) statement by the iconoclastic Dr. Vinay Prasad — who no doubt expresses what many medical educators have thought over the years, but never have been so bold to say:
https://twitter.com/VPrasadMDMPH/status/1114221315265679360
And since Tom Lehrer just turned 91, and this is a post about education, I can’t resist sharing this brilliant song and video:
April 7th, 2019
New York Times Highlights the Problem of Antimicrobial Resistance — and the Tricky Issue of Disclosure
Right there, on the homepage of today’s New York Times, our national paper of record — Sunday edition, no less! — appears this headline:
A Mysterious Infection, Spanning the Globe in a Climate of Secrecy
Most of this piece is about Candida auris, the highly resistant fungus that targets our most vulnerable patients — those with weakened immune systems due to extremes of age, comorbid medical problems, cancer chemotherapy, or immunosuppressive drugs.
The authors do an excellent job bringing attention to the seriousness of the problem. They provide some theories about its origin and cite the many challenges each Candida auris case brings to hospital workers, in particular those in charge of Infection Control.
But there’s a second message in this piece, one highlighted by the difference between the online headline and the one in print.
Online: A Mysterious Infection, Spanning the Globe in a Climate of Secrecy
Print: Fungus Immune to Drugs Quietly Sweeps the Globe
It’s that Climate of Secrecy phrase, implying there’s a widespread cover-up effort.
Indeed, there’s a distinct tone of blame in the article directed squarely at institutions that failed to disclose problems with Candida auris. One person quoted likened it to a restaurant failing to disclose that it had a food poisoning outbreak.
But with the caveat that I don’t work at the institutions cited in the article, I emphatically wish to state that we ID specialists strongly welcome all publicity about the seriousness of antimicrobial resistance.
In fact, if you want two messages about which we have 100% unanimity, here they are:
- Vaccines work, prevent illness, save lives, and save money — the risks are vastly outweighed by their many benefits.
- The overuse of antimicrobial agents leads to a dangerous increase in drug-resistant microorganisms, and this is a huge local, national, and global threat.
Read what Infection Control specialist Dr. Dan Diekema wrote after he saw the piece in the Times — he was “Happy to see” that this important issue had risen to such prominence:
Happy to see that an emerging, antimicrobial-resistant, healthcare-associated pathogen has made the FRONT PAGE of the NYT! The reporters do a good job placing C. auris in larger context..@PaulSaxMD @mike_edmond @eliowa 1/9 https://t.co/OH1ioEWJRT
— Dan Diekema (@dan_diekema) April 6, 2019
He (and all of us) are even happier that there’s another piece in the Times on antibiotic resistance, here describing how the combination of antibiotic overuse, crowding, and poor sanitation inexorably drives up resistance rates in low and middle income countries.
So, if there’s a cover-up about this important problem, it’s not coming from us ID doctors.
One last point — while I am all for transparency and disclosure if it improves patient safety, the public must realize that having patients with drug-resistant infections within the walls of a hospital by no means proves that these clinicians and Infection Control departments provide substandard care.
As noted above, it’s frequently the sickest, most complex, and vulnerable patients who develop these infections. Often they are transferred from other institutions after prolonged hospitalizations, with many weeks of antibiotic exposure before they even reach our inpatient wards, and they already harbor resistant bugs.
It would be a shame if tertiary-care hospitals viewed mandatory disclosures of resistant infections as a disincentive for providing care to these patients, who arguably need advanced care the most.
Meanwhile, here’s a wonderful summary of some key learning points about Candida auris — presciently sketched out by cartoonist-MD Dr. Grace Farris a couple of weeks before the Times piece was published. Thank you, Grace!
March 31st, 2019
The Problem with Research Posters — and a Bold Approach to Fixing Them
When submitting an abstract to a scientific meeting, you can usually expect one of three outcomes.
I’ve listed them below in order of preference, plus the messages the meeting organizers and abstract reviewers are not-so-subtly sending you:
- Oral Presentation: Congratulations! Your abstract has been accepted for an Oral Presentation — in other words, the work sounds so fascinating, so potentially important, we’d love to hear more. You’ll give a 10-minute slide presentation in front of hundreds (maybe thousands) of colleagues on a big stage, backed by a larger than life video feed of your face on our giant LCD screen — so remember to pluck those errant facial hairs beforehand.
- Research Poster: Congratulations, your study has been accepted as a Research Poster! Now, you must generate a single-slide PowerPoint file packed with text, figures, and bullet points, have it professionally printed as a bed-sheet sized poster, and then affix it to a mobile bulletin board during the conference. We’ll give you a designated time to stand by your poster to explain the results. But don’t be alarmed when hundreds of other researchers and their posters line up as well in a vast, industrially lit space. And when we say vast, we’re not kidding — an Airbus A380 might roll by on its way to the runway.
- Rejection: We’re sorry, your study was too weak and/or uninteresting to meet our high standards. We’ll probably tell you that there were many competitive submissions, which is supposed to make you feel better. But you can come to the meeting anyway, providing you pay the registration and housing fees.
While the oral presentation is clearly the winner here, the research poster is undoubtedly the most challenging — and much more numerous, so everyone has to do one sooner or later. Several reasons why posters fill us with dread:
- How do I know what to include on the poster? More isn’t always better, but that lesson is lost on all of us while preparing posters. The default position? More is more. Many of these posters have so much text that they would exceed word-limits on actual submitted manuscripts, if not Victorian novels.
- How to get noticed? This large poster with tiny text is simply hard to read — personally made worse by the fact that I’m at that stage of eye “health” where everything is either too far away or too close. As a result, most meeting participants experience research posters as a blur of information as they walk by. It doesn’t help that further distractions abound in the poster hall, including chance encounters with colleagues, friends, and the occasional giraffe, elephant or other large mammal. I mentioned that the poster halls were vast, didn’t I?
- What’s the best way to convey the information to the (rare) person who stops by and actually wants to discuss your poster further? Here you need a good “elevator pitch,” but I always feel kind of like the weather person on the news show. “And over here [gesturing], we have both the multivariable analysis and the 7-day forecast. Don’t forget your umbrella for Tuesday!”
- What if you get a bad poster location? Did I convey the vastness of these interior spaces with the above reference to the Airbus A380? To the giraffe/elephant? If you’d prefer another reference, I recall a time my poster was positioned in the back corner of a cavernous hall, so far from everything that I’m convinced Lewis and Clark would have skipped this part of the country as too remote or forbidding for habitation. I stood there a long time, just me and my poster, tumbleweeds rolling by … hello? Can anyone hear me?
- What do you do with the poster after the meeting? Many young researchers wonder how to transport the thing after the meeting, which isn’t exactly airline-friendly in shape. After years of experience, I’ve finally figured it out: Unless you have a specific need for the poster already scheduled, say, “Thank you for your service,” Marie Kondo-style, and toss it in the recycling bin. Problem solved!
Not all is lost with research posters, however — it’s still better than a rejection, much better. After all, some of the most important research starts its academic life as a research poster. In our field, the most notable example is the first case of HIV cure after stem cell transplant. Yep — originally “just” a research poster! Maybe it was the sample size (n=1).
Now, how to fix them. The topic is much on my mind since I stumbled across the work of Mike Morrison, a Ph.D. student in psychology.
After I reached out to him, he was kind enough to share this “short version” of why he tackled the problem:
User Experience (UX) Designer quits career and starts a PhD in Organizational Psychology. Goes insane from how horrifically inefficient the user experience of science is. Has serious health scare. Suddenly gets real motivated to fix the problem and speed up science. Starts with the poster.
His brave plan for research posters puts the main message right in the center — and BIG! — with supporting information along the side. I’ve embedded the key figure from his method at the top of this post; he generously shares some templates here.
So if you’re a medical or scientific researcher, do yourself a favor and watch the brilliant and entertaining video. I’ve been thinking about it since seeing it last week, and have already shared it with some collaborators — and now with all of you.
And for your next scientific meeting — will you be brave enough to try it?